研報掘金丨中郵證券:中科星圖業績有望逐步釋放,首予“買入”評級
中郵證券研報指出,中科星圖(688568.SH)爲國內數字地球產品研發與產業化的領軍企業,具有領先的AI 技術和數據資源,上市以來業績平穩增長,星圖雲打造第二增長曲線,抓住低空經濟產業機遇,業績有望逐步釋放,首次覆蓋,給予“買入”評級。在技術與戰略方面,中科星圖掌握多項核心技術,包括跨域融合算力網、多平臺空天大數據可視化及應用開發技術、低空空域數字化構建技術等。截止三季度,公司實現營業總收入20.07億元,同比去年增長43.44%,歸母淨利潤爲1.46億元,同比去年增長41.27%。此外,公司還與多個地方政府和機構合作,打造低空經濟發展的示範標杆,推動低空經濟在不同區域的落地應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.